Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions announced a $22.3 million modification to its delivery order for BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The initial delivery, worth about $7.4 million, is set to commence this year, with subsequent deliveries planned through 2027. This contract reinforces Emergent's ongoing relationship with the Department of War.

Market Sentiment Analysis

POSITIVE FACTORS

  • Emergent BioSolutions secured a $22.3 million order.
  • First delivery valued at approximately $7.4 million begins this year.
  • Supply contract extends through 2027.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
COVID-HIG
Phase 1 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027. This order is under Emergent’s existing indefinite-delivery/

Frequently Asked Questions

What is the value of the delivery order modification?

The modification is valued at up to $22.3 million.

When will the first delivery of BioThrax occur?

The first delivery is set to begin this year.

How much is the first delivery worth?

The first delivery is valued at approximately $7.4 million.

When are the remaining deliveries expected?

Remaining deliveries are expected to occur in 2027.

ShareAdd on Google
Tags: EBS Emergent BioSolutions BioThrax anthrax vaccine U.S. Department of War
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$176M liquidity · $0M/mo burn
Low dilution risk
Lead asset
COVID-HIGPhase 1
SARS-CoV-2 Infection →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →